Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Stocks - Halliburton, Noble Energy Rise Premarket; Facebook Drops

Published 07/20/2020, 07:58 AM
Updated 07/20/2020, 07:58 AM
© Reuters.

By Peter Nurse 

Investing.com -- Stocks in focus in premarket trade on Monday, July 20th. Please refresh for updates.

  • Halliburton (NYSE:HAL) stock rose 5.4% after the oil and gas services company reported a surprise profit of 5 cents a share, after adjusting for a $2.1 billion impairment charge. Second-quarter revenue fell 46% on the year, however, as the number of drilling rigs contracted by U.S. companies plummeted to decade-lows.
  • Chevron (NYSE:CVX) stock fell 0.2% after the oil giant confirmed plans to buy Noble Energy (NASDAQ:NBL), whose stock rose over 10%, in an all-stock transaction valued at $5 billion,]. That's the largest deal in the sector since the coronavirus pandemic erupted.
  • Facebook (NASDAQ:FB) stock fell 0.8% after the Wall Street Journal reported that Walt Disney (NYSE:DIS), one of the biggest ad spenders, has become the latest company to slash its advertising spending on the social media giant over its handling of hate speech and controversial content.
  • Ebay (NASDAQ:EBAY) stock rose 1.8% after the Wall Street Journal reported that the e-commerce giant is in advanced talks to sell its classified-ads unit to Norwegian group Adevinta in a move to refocus on its core marketplace business.
  • Walmart (NYSE:WMT) stock rose 0.2%, after the retail colossus said it will require customers to wear face coverings at all of its stores, making it the largest retailer to introduce the controversial policy.
  • Moderna (NASDAQ:MRNA) stock rose 1.9% despite JPMorgan (NYSE:JPM) downgrading its investment stance on the biotech company to neutral from overweight, largely on valuation. The stock is up 386% year to date.
  • AstraZeneca (NYSE:AZN) ADR rose 1.3% with the U.K.-based pharmaceutical set Monday to publish in the medical journal The Lancet the results of the latest trial of its experimental drug being developed in conjunction with Oxford University.
  • Denbury Resources (NYSE:DNR) stock rose over 46% after a press report emerged that the company was subject to a buyout offer. However, Denbury's CEO said on Bloomberg that his company did not put out the press release about the buyout offer, and that it appears to be "completely fraudulent."
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.